<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572815</url>
  </required_header>
  <id_info>
    <org_study_id>RG1005588</org_study_id>
    <secondary_id>NCI-2020-02617</secondary_id>
    <secondary_id>10421</secondary_id>
    <secondary_id>R01FD006836</secondary_id>
    <nct_id>NCT04572815</nct_id>
  </id_info>
  <brief_title>Ustekinumab for the Prevention of Acute Graft Versus Host Disease After Unrelated Donor Hematopoietic Cell Transplant</brief_title>
  <official_title>Randomized, Placebo-Controlled, Phase II Trial Examining Ustekinumab for Prevention of Graft Vs. Host Disease After Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well ustekinumab works in preventing acute graft versus host&#xD;
      disease after unrelated donor hematopoietic cell transplant. Sometimes the transplanted cells&#xD;
      from a donor can attack the body's normal tissues (called graft-versus-host disease). Giving&#xD;
      ustekinumab after the transplant may help prevent acute graft versus host disease by&#xD;
      controlling the body's immune response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Between 4 and 72 hours prior to start of HCT conditioning therapy, patients receive&#xD;
      ustekinumab intravenously (IV). Beginning 8 weeks after receiving IV ustekinumab, patients&#xD;
      receive ustekinumab subcutaneously (SC) on days 50 (+/- 5 days), 100 (+/- 7 days), and 160&#xD;
      (+/- 7 days) post-HCT in the absence of grade III-IV acute GVHD, disease relapse or&#xD;
      unacceptable toxicity. NOTE: HCT infusion takes place on day 0.&#xD;
&#xD;
      ARM II: Between 4 and 72 hours prior to start of HCT conditioning therapy, patients receive a&#xD;
      placebo IV. Beginning 8 weeks after IV placebo, patients receive a placebo SC on days 50 (+/-&#xD;
      5 days), 100 (+/- 7 days), and 160 (+/- 7 days) post-HCT in the absence grade III-IV acute&#xD;
      GVHD, of disease relapse, or unacceptable toxicity. NOTE: HCT infusion takes place on day 0.&#xD;
&#xD;
      After completion of study, patients are followed up at 6, 9, 12, 18, and 24 months post-HCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade II-IV acute graft versus host disease (GVHD) survival</measure>
    <time_frame>At 6 months post-hematopoietic cell transplantation (HCT)</time_frame>
    <description>Will be treated as a binary outcome, and the Cochran-Mantel-Haenszel test will be used to compare the two groups based on the stratification factors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of grade II-IV and grade III-IV acute GVHD</measure>
    <time_frame>At 100 days post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of grade II-IV and grade III-IV acute GVHD</measure>
    <time_frame>At 6 months post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute GVHD organ staging, overall grading, and classification</measure>
    <time_frame>From time of HCT, assessed up to day 100 post-HCT</time_frame>
    <description>Minnesota risk criteria will be used to assess organ involvement, individual organ staging, and overall acute GVHD grade. Risk classification will be performed per MacMillan et al.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of overall chronic GVHD</measure>
    <time_frame>Up to 2 years post-HCT</time_frame>
    <description>Will be assessed at serial study visits, and scored according to National Institutes of Health Consensus criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of moderate-severe chronic GVHD</measure>
    <time_frame>Up to 2 years post-HCT</time_frame>
    <description>Will be assessed at serial study visits, and scored according to National Institutes of Health Consensus criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-HCT relapse</measure>
    <time_frame>From time of HCT assessed up to 2 years post-HCT</time_frame>
    <description>Relapse is defined as hematologic relapse or any unplanned intervention (including withdrawal of immune suppression) to prevent progression of disease in patients with evidence (molecular, cytogenetic, flow cytometric, radiographic) of malignant disease. Will be compared using either the log-rank test (if no competing risks) or Gray's test (if competing risks are present). For time-to-event endpoints with competing risks, the log-rank test will also be used for exploratory purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality</measure>
    <time_frame>From time of HCT assessed up to 2 years post-HCT</time_frame>
    <description>Non-relapse mortality indicates death with primary malignancy that served as HCT indication in remission. Will be compared using either the log-rank test (if no competing risks) or Gray's test (if competing risks are present). For time-to-event endpoints with competing risks, the log-rank test will also be used for exploratory purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>From time of HCT assessed up to 2 years post-HCT</time_frame>
    <description>Relapse is defined as hematologic relapse or any unplanned intervention (including withdrawal of immune suppression) to prevent progression of disease in patients with evidence (molecular, cytogenetic, flow cytometric, radiographic) of malignant disease. Will be compared using either the log-rank test (if no competing risks) or Gray's test (if competing risks are present). For time-to-event endpoints with competing risks, the log-rank test will also be used for exploratory purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From time of HCT assessed up to 2 years post-HCT</time_frame>
    <description>Will be compared using either the log-rank test (if no competing risks) or Gray's test (if competing risks are present). For time-to-event endpoints with competing risks, the log-rank test will also be used for exploratory purposes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Hematologic and Lymphocytic Disorder</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (ustekinumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Between 4 and 72 hours prior to start of HCT conditioning therapy, patients receive ustekinumab IV. Beginning 8 weeks after receiving IV ustekinumab, patients receive ustekinumab SC on days 50 (+/- 5 days), 100 (+/- 7 days), and 160 (+/- 7 days) post-HCT in the absence of grade III-IV acute GVHD, disease relapse or unacceptable toxicity. NOTE: HCT infusion takes place on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Between 4 and 72 hours prior to start of HCT conditioning therapy, patients receive a placebo IV. Beginning 8 weeks after IV placebo, patients receive a placebo SC on days 50 (+/- 5 days), 100 (+/- 7 days), and 160 (+/- 7 days) post-HCT in the absence of grade III-IV acute GVHD, disease relapse, or unacceptable toxicity. NOTE: HCT infusion takes place on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given IV and SC</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (ustekinumab)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (ustekinumab)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>Given IV and SC</description>
    <arm_group_label>Arm I (ustekinumab)</arm_group_label>
    <other_name>CNTO 1275</other_name>
    <other_name>CNTO1275</other_name>
    <other_name>Immunoglobulin G1, Anti-(Human Interleukin-12 Subunit beta (IL-12B, CLMF p40, NKSF2)) (Human Monoclonal CNTO 1275 gamma1-chain), Disulfide with Human Monoclonal CNTO 1275 kappa-chain, Dimer</other_name>
    <other_name>Stelara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Hematologic malignancy or disorder requiring allogeneic hematopoietic cell&#xD;
             transplantation&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 45%&#xD;
&#xD;
          -  Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and&#xD;
             diffusion capacity of the lung for carbon monoxide (DLCO) &gt;= 50% of predicted values&#xD;
             on pulmonary function tests&#xD;
&#xD;
          -  Transaminases (aspartate aminotransferase [AST], aspartate aminotransferase [ALT]) &lt; 3&#xD;
             times upper limit of normal values&#xD;
&#xD;
          -  Creatinine clearance &gt;= 50 cc/min&#xD;
&#xD;
          -  Karnofsky performance status score &gt;= 60%&#xD;
&#xD;
          -  HCT donor is at least 8/8 (matched at human leukocyte antigen [HLA]-A, -B, -C, -DRB1)&#xD;
             matched with the recipient&#xD;
&#xD;
          -  PBSC (peripheral blood mobilized stem cells) as graft source&#xD;
&#xD;
          -  Fully myeloablative, reduced-toxicity ablative, or reduced-intensity conditioning&#xD;
             regimens&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infection not controlled with appropriate antimicrobial therapy&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection&#xD;
&#xD;
          -  Anti-thymocyte globulin (ATG) as part of the conditioning regimen or GVHD prophylaxis&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Subjects of childbearing age unwilling to use an effective birth control method or&#xD;
             refrain from sexual intercourse until 3 months after last dose of study drug&#xD;
&#xD;
          -  Non-myeloablative conditioning regimens&#xD;
&#xD;
          -  Prior allogeneic transplant&#xD;
&#xD;
          -  Non-malignant blood disorders (e.g. sickle cell disease, aplastic anemia)&#xD;
&#xD;
          -  Positive screening test for tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie J. Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie J. Lee</last_name>
    <phone>206-667-6190</phone>
    <email>sjlee@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center,</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryotaro Nakamoto</last_name>
      <phone>626-256-4673 x82405</phone>
      <email>rnakamoto@coh.org</email>
    </contact>
    <investigator>
      <last_name>Ryotaro Nakamoto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Pidala</last_name>
      <phone>813-745-2256</phone>
      <email>joseph.pidala@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Pidala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Chen</last_name>
      <phone>716-834-4074</phone>
      <email>George.chen@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>George Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie J. Lee</last_name>
      <phone>206-667-6190</phone>
      <email>sjlee@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Stephanie J. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-12</mesh_term>
    <mesh_term>Ustekinumab</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

